Thursday, December 21, 2023 9:51:55 AM
Looking for a couple of gentlemanly dollars
As of Dec-21-20239:49:07 AM ET
https://stockcharts.com/h-sc/ui
The News
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
BENZINGA
Immunovant Inc (IMVT.NaE) , on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in patients with Graves' disease.
Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism).
The company says the results show that batoclimab meaningfully exceeded 50% response rates.
Consistent with studies of batoclimab in other indications, 680 mg administered subcutaneously (SC) in the initial cohort demonstrated an IgG reduction of up to 87%, with a mean IgG reduction of 81% after 12 weeks of treatment.
The 340 mg IgG reductions were lower. A similar dose response was observed for anti-TSHR autoantibodies, with deeper reductions observed following treatment with 680 mg of SC batoclimab compared to 340 mg of SC batoclimab.
In addition, numerically higher responses were observed following treatment with 680 mg of batoclimab across a range of clinical parameters compared to treatment with 340 mg of batoclimab.
Batoclimab was generally well tolerated, with no new safety signals observed in the initial data set.
Recent IMVT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2024 10:02:50 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2024 10:01:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2024 09:11:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2024 09:09:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2024 09:08:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2024 10:15:40 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2024 10:11:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2024 11:49:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 11:42:10 AM
- Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 • GlobeNewswire Inc. • 11/07/2024 11:30:00 AM
- Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting • GlobeNewswire Inc. • 10/29/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2024 08:23:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/18/2024 08:31:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/18/2024 08:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/18/2024 08:27:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 08:04:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2024 08:02:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:40:38 AM
- Roivant Provides Update on Graves’ Disease Development Program • GlobeNewswire Inc. • 09/09/2024 11:00:00 AM
- Immunovant Provides Update on Graves’ Disease Development Program • GlobeNewswire Inc. • 09/09/2024 07:55:00 AM
- Immunovant to Host Graves’ Disease Program Update on September 9, 2024 • GlobeNewswire Inc. • 09/05/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:14:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:11:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:10:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:07:18 PM
FEATURED Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology • Jan 9, 2025 8:49 AM
UAV Corp. (UMAV) Further Reduces Authorized Shares to 500 Million • UMAV • Jan 8, 2025 2:27 PM
Fifty 1 Labs, Inc. Launches Dedicated Website for Shareholders and Investors, Company now current with OTC Markets • CAFI • Jan 7, 2025 9:00 AM
EzFill Holdings, Inc. Successfully Closes Acquisition of Shell Fleet, Accelerating Nationwide Mobile Fueling Expansion • EZFL • Jan 7, 2025 8:35 AM
CGRA Signs Binding Term Sheet to Merge With American Infrastructure Corporation, a Subsidiary of Nasdaq-listed American Resources Corporation (Nasdaq: AREC) • CGRA • Jan 6, 2025 10:31 AM
UAV Corp (UMAV) Working on Securing $1.5 Billion in Contracts and Announces Groundbreaking Partnership with Atlantic Industrial Group • UMAV • Jan 6, 2025 9:26 AM